RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising new combo therapy targets Hard-to-Treat blood cancer
Disease control OngoingThis study tests whether adding the drug talquetamab to standard treatments (daratumumab and pomalidomide) helps people with multiple myeloma that has come back or stopped responding to prior therapy. About 864 participants will receive one of three drug combinations. The main go…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 08:39 UTC
-
New drug SG301 tested in blood cancer patients who have run out of options
Disease control OngoingThis early-stage study tests a new drug called SG301 in 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug mo…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:38 UTC
-
New hope for Tough-to-Treat myeloma: talquetamab access program opens
Disease control APPROVED_FOR_MARKETINGThis program offers talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. It is for those who have tried all available therapies and cannot join a clinical trial. The goal is to provide access before full approval, helping co…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
Last-Resort drug offered to desperate myeloma patients
Disease control NO_LONGER_AVAILABLEThis program gives patients with multiple myeloma that has come back or not responded to other treatments access to talquetamab, an experimental drug. It is for people who have no other options left. The goal is to control the disease, not cure it.
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New drug teclistamab takes on tough myeloma in major trial
Disease control OngoingThis study tests whether teclistamab, an immunotherapy, works better than standard drug combinations (PVd or Kd) for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior treatments. About 614 adults will take part. The goal is to see if teclist…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New manufacturing process for myeloma drug tested in 108 patients
Disease control OngoingThis study tests whether a new way of making teclistamab works as well as the current version in people with multiple myeloma that has come back or stopped responding to treatment. About 108 participants will receive either the old or new version, and researchers will measure dru…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New triple therapy aims to extend life in hard-to-treat blood cancer
Disease control OngoingThis phase 3 study tests whether adding the experimental drug mezigdomide to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to treatment. About 606 participants will be randomly assigned to re…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 20, 2026 11:57 UTC